Literature DB >> 17552032

Immunotherapy of hepatoma with a monoclonal antibody against murine endoglin.

Guang-Hong Tan1, Feng-Ying Huang, Hua Wang, Yong-Hao Huang, Ying-Ying Lin, Yue-Nan Li.   

Abstract

AIM: To explore the capability of a monoclonal antibody (mAb) against murine endoglin to inhibit tumor angiogenesis and suppression of hepatoma growth in murine models.
METHODS: A monoclonal antibody against murine endoglin was purified by affinity chromatography and passively transfused through tail veins in two murine hepatoma models. Tumor volume and survival time were observed at three-day intervals for 48 d. Microvessels in tumor tissues were detected by immunohistochemistry against CD31, and angiogenesis in vivo was determined by alginate encapsulated assay. In addition, tumor cell apoptosis was detected by TUNEL assay.
RESULTS: Passive immunotherapy with anti-endoglin mAb could effectively suppress tumor growth, and prolonged the survival time of hepatoma-bearing mice. Angiogenesis was apparently inhibited within the tumor tissues, and the vascularization of alginate beads was also reduced in the mice passively transfused with anti-endoglin mAb. In addition, increased apoptotic cells were observed within the tumor tissues from the mice passively transfused with anti-endoglin mAb.
CONCLUSION: Passive immunotherapy with anti-endoglin mAb effectively inhibits tumor growth via inhibiting tumor angiogenesis and increasing tumor cell apoptosis, which may be highly correlated with the blockage of endoglin-related signal pathway induced by anti-endoglin mAb.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17552032      PMCID: PMC4146767          DOI: 10.3748/wjg.v13.i17.2479

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

Review 1.  Angiogenesis.

Authors:  J Folkman; Y Shing
Journal:  J Biol Chem       Date:  1992-06-05       Impact factor: 5.157

2.  What is the evidence that tumors are angiogenesis dependent?

Authors:  J Folkman
Journal:  J Natl Cancer Inst       Date:  1990-01-03       Impact factor: 13.506

Review 3.  Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents.

Authors:  R S Kerbel
Journal:  Bioessays       Date:  1991-01       Impact factor: 4.345

4.  Cell turnover of capillaries.

Authors:  R L Engerman; D Pfaffenbach; M D Davis
Journal:  Lab Invest       Date:  1967-12       Impact factor: 5.662

Review 5.  Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies.

Authors:  H F Dvorak; J A Nagy; A M Dvorak
Journal:  Cancer Cells       Date:  1991-03

6.  Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line.

Authors:  A Gougos; M Letarte
Journal:  J Immunol       Date:  1988-09-15       Impact factor: 5.422

Review 7.  Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies.

Authors:  E Fonsatti; L Sigalotti; P Arslan; M Altomonte; M Maio
Journal:  Curr Cancer Drug Targets       Date:  2003-12       Impact factor: 3.428

8.  Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.

Authors:  Xinwei She; Fumihiko Matsuno; Naoko Harada; Hilda Tsai; Ben K Seon
Journal:  Int J Cancer       Date:  2004-01-10       Impact factor: 7.396

9.  Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.

Authors:  Y Haruta; B K Seon
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

10.  Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen.

Authors:  Guang-Hong Tan; Yu-Quan Wei; Ling Tian; Xia Zhao; Li Yang; Jiong Li; Qiu-Ming He; Yang Wu; Yan-Jun Wen; Tao Yi; Zhen-Yu Ding; Bin Kan; Yong-Qiu Mao; Hong-Xin Deng; Hong-Li Li; Chun-Hua Zhou; Chun-Hua Fu; Fei Xiao; Xiao-Wei Zhang
Journal:  Eur J Immunol       Date:  2004-07       Impact factor: 5.532

View more
  2 in total

1.  Endoglin promotes angiogenesis in cell- and animal-based models of retinal neovascularization.

Authors:  Joshua M Barnett; Sandra Suarez; Gary W McCollum; John S Penn
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-26       Impact factor: 4.799

2.  Gene Electrotransfer of Plasmid with Tissue Specific Promoter Encoding shRNA against Endoglin Exerts Antitumor Efficacy against Murine TS/A Tumors by Vascular Targeted Effects.

Authors:  Monika Stimac; Tanja Dolinsek; Ursa Lampreht; Maja Cemazar; Gregor Sersa
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.